KWMG
ZYNE

King Wealth Management Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

King Wealth Management Group’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,000
Closed -$20K – 151
2023
Q3 		$20K Hold
16,000
– – ﹤0.01% 144
2023
Q2 		$5K Hold
16,000
– – ﹤0.01% 150
2023
Q1 		$7K Hold
16,000
– – ﹤0.01% 148
2022
Q4 		$8K Hold
16,000
– – ﹤0.01% 141
2022
Q3 		$12K Hold
16,000
– – ﹤0.01% 151
2022
Q2 		$18K Hold
16,000
– – ﹤0.01% 159
2022
Q1 		$33K Buy
+16,000
New +$38K 0.01% 169
2021
Q3 		– Sell
-16,000
Closed -$85K – 187
2021
Q2 		$85K Hold
16,000
– – 0.02% 170
2021
Q1 		$74K Hold
16,000
– – 0.02% 159
2020
Q4 		$53K Buy
+16,000
New +$60.8K 0.01% 153

King Wealth Management Group's ZYNE Position: Q4 2023 in Review

King Wealth Management Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 16,000 shares — an estimated $20K sold.

King Wealth Management Group first reported a position in ZYNE in Q4 2020 and held it in 10 quarters. The position peaked at $85K in Q2 2021. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.

  • King Wealth Management Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
  • King Wealth Management Group sold 16,000 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $20K.
  • King Wealth Management Group first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2020 and held it in 10 quarters.
  • King Wealth Management Group's Zynerba Pharmaceuticals, Inc position peaked at $85K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.

Based on King Wealth Management Group's 13F filing for Q4 2023, filed 8 Feb 2024.